A study investigated the efficacy and safety of soluble guanylate cyclase (sGC) stimulators and activators in the treatment of chronic kidney disease (CKD), a major health problem worldwide.[1] Researchers analyzed ten studies and found that administration of these substances led to significant positive effects: a decrease in kidney weight (by 1.55 units), a decrease in systolic blood pressure (by 3.52 units), and a decrease in serum uric acid (by 3.52 units).[1] Treatment also improved kidney function, as demonstrated by reductions in serum creatinine (by 3.24 units) and blood urea nitrogen (by 3.53 units).[1] The efficacy of treatment was consistent regardless of the specific type of sGC, but could differ depending on the type of CKD.[1] However, the study did not show any significant effect on the total body weight of the patients.[1] The authors conclude that these substances have renoprotective effects and may offer additional therapeutic options for various types of CKD.[1]